OncoMatch/Clinical Trials/NCT05777824
Postoperative Management for HNSCC Based on Pathological Response of Induction Chemotherapy and Immunotherapy
Is NCT05777824 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies anti-PD-1 or PD-L1 antibody for head and neck cancer.
Treatment: anti-PD-1 or PD-L1 antibody — To develop postoperative stratification treatment for patients who have received induction chemotherapy and immunotherapy in locally advanced head and neck cancers. Risk stratification is based on clinical characteristics and pathological responses. In order to achieve no inferior survival rate and a lower treatment-related toxicity rate than the standard treatment.
Check if I qualifyExtracted eligibility criteria
Cancer type
Head and Neck Squamous Cell Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: induction chemotherapy — preoperative
received induction chemotherapy plus immunotherapy, followed by surgery
Must have received: immunotherapy — preoperative
received induction chemotherapy plus immunotherapy, followed by surgery
Must have received: surgery — post-induction
received induction chemotherapy plus immunotherapy, followed by surgery
Cannot have received: systemic anti-tumor therapy
Exception: before induction chemotherapy and immunotherapy
Received any systemic anti-tumor therapy for target lesions before induction chemotherapy and immunotherapy
Cannot have received: radiation therapy
Exception: head and neck region
Previously experienced head and neck radiation therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify